drugset
drugset / Trial / NCT05162053

PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

NCT05162053 ↗

Phase 1 Completed 128 enrolled Jiangsu vcare pharmaceutical technology co., LTD
RandomizedCrossoverOpen-labelTreatment

Summary

This clinical study will adopt an open-label, randomized, multiple-dose, two-crossover design to explore the pharmacokinetic and pharmacodynamic profiles of Vicagrel Capsules and Clopidogrel Tablets in Healthy Subjects with Different CYP2C19 Metabolizers

Timeline

Start
2021-12-09
Primary completion
2022-11-03
Completion
2022-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule — Oral
Subject SUMECIGREL Small molecule — Oral

Indications

acute coronary syndrome